C12N 9/1211
Thymidine kinase
Official title: {Thymidine kinase (2.7.1.21)}
C12N9/1211 (Thymidine kinase) appears on 124 US grants and 158 published applications in this corpus.
Search patents in C12N- Granted patents
- 124
- Published applications
- 158
- Assignees
- 111
- Inventors
- 377
- Latest grant
- 13 Jan 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1995 | 1 | 0 |
| 1996 | 2 | 0 |
| 1997 | 3 | 0 |
| 1998 | 12 | 0 |
| 1999 | 10 | 0 |
| 2000 | 6 | 0 |
| 2001 | 10 | 3 |
| 2002 | 5 | 4 |
| 2003 | 6 | 10 |
| 2004 | 4 | 7 |
| 2005 | 1 | 3 |
| 2006 | 5 | 8 |
| 2007 | 0 | 1 |
| 2008 | 1 | 4 |
| 2009 | 2 | 7 |
| 2010 | 3 | 6 |
| 2011 | 5 | 11 |
| 2012 | 4 | 3 |
| 2013 | 4 | 5 |
| 2014 | 5 | 7 |
| 2015 | 3 | 5 |
| 2016 | 2 | 3 |
| 2017 | 2 | 7 |
| 2018 | 7 | 5 |
| 2019 | 4 | 8 |
| 2020 | 2 | 6 |
| 2021 | 0 | 5 |
| 2022 | 6 | 11 |
| 2023 | 3 | 8 |
| 2024 | 3 | 9 |
| 2025 | 2 | 3 |
| 2026 | 1 | 9 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- DNA, expression vector, transcript, cell, pharmaceutical composition, and medicine13 Jan 2026US 12,521,450 B2Hitachi, Ltd.
- Gene therapy for diseases caused by unbalanced nucleotide pools including mitochondrial DNA depletion syndromes23 Sep 2025US 12,419,970 B2The Trustees of Columbia University in the City of New York
- Oncolytic virus improved in safety and anticancer effect11 Feb 2025US 12,220,437 B2Bionoxx Inc.
- Cyclin G1 inhibitors and related methods of treating cancer24 Dec 2024US 12,173,041 B2Delta Next-Gene, LLC
- Gene therapy vector with minimizing recombination, recombinant retrovirus comprising the vector, and pharmaceutical composition for preventing or treating cancer comprising the recombinant retrovirus30 Apr 2024US 11,970,708 B2ArtiCure, Inc.
- Functional nucleic acid molecule and method20 Aug 2026US 2026/0241035 A1The University Court of the University of Edinburgh
- Ovarian cancer risk prediction13 Aug 2026US 2026/0235608 A1Arocell AB
- Methods for treating liver cancer by genomic targeting9 Jul 2026US 2026/0191996 A1University of Pittsburgh—Of the Commonwealth System of Higher Education
- Vector for expression of chimeric antigen receptor and uses thereof11 Jun 2026US 2026/0158067 A1GenVivo, Inc.
- Stem cell based delivery of tumor-specific retroviral vectors21 May 2026US 2026/0139275 A1Abintus Bio, Inc.
Most cited
By later US patents
- Somatic gene therapy to cells associated with fluid spaces87US 5,770,580 ABaylor College of Medicine · 1998
- Anti-pathogen system and methods of use thereof79US 6,221,355 B1Washington University · 2001
- Recombinant retroviruses57US 5,716,613 AChiron Viagene, Inc. · 1998
- Anti-pathogen system and methods of use thereof57US 6,645,501 B2Washington University · 2003
- Methods for administration of recombinant gene delivery vehicles for treatment of hemophilia and other disorders57US 6,818,439 B1Chiron Corporation · 2004